AI Summary & Key Takeaways
AI InsightConclusion: According to the present findings, future studies should investigate alternative pathways of multidrug resistance in order to arrive at a better understanding of treatment failure in lymphoma patients.
📌 3 Key Takeaways
Abstract
Objective: Multidrug resistance is a cause of treatment failure in patients with malignant lymphoma; however, the frequency and clinical relevance of multidrug resistance protein expression are unclear. The present study aimed to investigate expression of the most common multidrug resistance proteins in a group of lymphoma patients. Material and Methods: The study included 44 previously untreated lymphoma patients (non-Hodgkin’s lymphoma [n = 21], non-malignant lymphadenopathy [n = 13], and Hodgkin’s lymphoma [n = 10]). MDR1, MRP, and LRP expression was assessed via quantitative PCR of lymph node biopsy specimens. Results: In the non-Hodgkin’s lymphoma group MDR1 was positive in 23.8% (5/21) of the patients, MRP was positive in 57.14% (12/21), and LRP was positive in 90.47% (19/21). In the non-malignant lymphadenopathy group, MDR1 was positive in 46.15% (6/13) of the patients, MRP was positive in 84.61% (11/13), and LRP was positive in 100% (13/13). In the Hodgkin’s lymphoma group MDR1 was positive in 50% (5/10) of the patients, MRP was positive in 50% (5/10), and LRP was positive in 80% (8/10). MDR1, MRP, and LRP expression did not differ between the 3 groups. Furthermore, MDR1, MRP, and LRP expression wasn’t associated with tumor stage, response to first-line therapy, the erythrocyte sedimentation rate, or C reactive protein, beta 2 microglobulin, serum lactate dehydrogenase, and albumin levels. Additionally, survival time in the MDR1- and MRP-positive, and MDR1- and MRP-negative patients did not differ (comparison of LRP was not possible due to the small number of LRP-negative patients). Conclusion: According to the present findings, future studies should investigate alternative pathways of multidrug resistance in order to arrive at a better understanding of treatment failure in lymphoma patients.
Özet
Amaç: Çoklu ilaç direnci malign lenfomalarda tedavi başarısızlığının nedenlerindendir. Fakat çoklu ilaç direnci proteinlerinin sıklığı ve klinik önemiyle ilgili çelişkiler mevcuttur. Biz bu çalışmada lenfomalı hastalarımızda en sık görülen çoklu ilaç direnci proteinlerinin ifadelerini araştırdık. Gereç ve Yöntemler: Çalışmaya daha önce tedavi almamış 44 hasta (21 non Hodgkin lenfoma, 13 malign olmayan lenfadenopati, 10 Hodgkin lenfoma) alındı. MDR1, MRP ve LRP ifadeleri lenf nodu biyopsi örneklerinde kantitatif PCR ile değerlendirildi. Bulgular: Non Hodgkin lenfomada MDR1 %23.8 (5/21), MRP %57.14 (12/21), LRP %90.47 (19/21) pozitifti. Malign olmayan lenfadenopatili hastalarda MDR1 %46.15 (6/13), MRP %84.61 (11/13), LRP %100 (13/13) pozitifti. Hodgkin lenfomada MDR1 %50 (5/10), MRP %50 (5/10), LRP %80 (8/10) pozitifti. MDR1, MRP ve LRP ifadeleri 3 grup arasında farklı değildi. İfadeler tümör evresi, eritrosit sedimantasyon hızı, C reaktif protein, beta 2 mikroglobulin, ilk sıra tedaviye yanıt, serum laktat dehidrogenaz ve albumin düzeyiyle ilişkili değildi. MDR1 ve MRP pozitif ve negatif hastaların yaşam süreleri arasında da fark bulamadık (LRP pozitif ve negatif hastalar arası karşılaştırma yapmak az hasta sayısı nedeniyle mümkün olmadı). Sonuç: Verilerimize göre, bu grup hastalardaki tedavi başarısızlığını aydınlatmak için gelecekte yapılacak çalışmalar çoklu ilaç direncinin alternatif yolaklarına yönlendirilebilir.